CPS Technologies-European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

Businesswire·2025-10-29 18:45

公司动态 - 默克公司的抗PD-1疗法KEYTRUDA®获得欧洲委员会批准作为单药疗法 [1] - 该批准用于治疗可切除的局部晚期头颈部鳞状细胞癌成年患者 [1] - 治疗方案包括作为新辅助治疗开始随后与放疗联合作为辅助治疗之后继续作为单药治疗 [1]